Skip to Content


In the US, Fingolimod (fingolimod systemic) is a member of the drug class selective immunosuppressants and is used to treat Multiple Sclerosis.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Selective immunosuppressant

Treatment of multiple sclerosis, MS

Sphingosine 1-phosphate (S1P) receptor modulator

Chemical Name

2-amino-2-[2-(4-octylphenyl]etylpropane-1,3-diol (WHO)

Foreign Names

  • Fingolimodum (Latin)
  • Fingolimod (German)
  • Fingolimod (French)
  • Fingolimod (Spanish)

Generic Names

Brand Names

  • Gilenya
    Novartis, Colombia; Novartis, Greece; Novartis, Lithuania; Novartis, Poland; Novartis, Slovakia; Novartis, Thailand; Novartis, Tunisia; Novartis, United States; Novartis Europharm, Cyprus; Novartis Pharmaceuticals, Australia
  • Gilenia
    Novartis Pharma, Russian Federation
  • Gilenya
    Emra-Med Arzneimittel, Austria; Haemato Pharm, Austria; NewNeopharm, Austria; Novartis, Argentina; Novartis, Bosnia & Herzegowina; Novartis, Belgium; Novartis, Chile; Novartis, Czech Republic; Novartis, Denmark; Novartis, Finland; Novartis, France; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Hungary; Novartis, Ireland; Novartis, Iceland; Novartis, Japan; Novartis, Latvia; Novartis, Mexico; Novartis, Malaysia; Novartis, Norway; Novartis, New Zealand; Novartis, Portugal; Novartis, Romania; Novartis, Sweden; Novartis Europharm, Austria; Novartis Farma, Italy; Novartis Farmaceutica, Spain; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom
  • Imusera
    Tanabe Mitsubishi Pharma, Japan


BANBritish Approved Name
BANMBritish Approved Name (Modified)
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.